ID   PGCA_HUMAN              Reviewed;        2530 AA.
AC   P16112; B9EK55; E7ENV9; E7EX88; H0YM81; Q13650; Q9UCD3; Q9UCP4; Q9UCP5;
AC   Q9UDE0;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   28-MAR-2018, sequence version 3.
DT   03-AUG-2022, entry version 225.
DE   RecName: Full=Aggrecan core protein;
DE   AltName: Full=Cartilage-specific proteoglycan core protein;
DE            Short=CSPCP;
DE   AltName: Full=Chondroitin sulfate proteoglycan core protein 1;
DE            Short=Chondroitin sulfate proteoglycan 1;
DE   Contains:
DE     RecName: Full=Aggrecan core protein 2;
DE   Flags: Precursor;
GN   Name=ACAN; Synonyms=AGC1, CSPG1, MSK16;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND VARIANTS THR-913 AND VAL-1765.
RC   TISSUE=Chondrocyte;
RX   PubMed=1985970; DOI=10.1016/s0021-9258(17)35257-2;
RA   Doege K.J., Sasaki M., Kimura T., Yamada Y.;
RT   "Complete coding sequence and deduced primary structure of the human
RT   cartilage large aggregating proteoglycan, aggrecan. Human-specific repeats,
RT   and additional alternatively spliced forms.";
RL   J. Biol. Chem. 266:894-902(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R., Fahey J.,
RA   Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G., Johnson E.,
RA   Jones C., Kamat A., Kaur A., Locke D.P., Madan A., Munson G., Jaffe D.B.,
RA   Lui A., Macdonald P., Mauceli E., Naylor J.W., Nesbitt R., Nicol R.,
RA   O'Leary S.B., Ratcliffe A., Rounsley S., She X., Sneddon K.M.B.,
RA   Stewart S., Sougnez C., Stone S.M., Topham K., Vincent D., Wang S.,
RA   Zimmer A.R., Birren B.W., Hood L., Lander E.S., Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human chromosome
RT   15.";
RL   Nature 440:671-675(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANTS LEU-864;
RP   ILE-930; THR-939; ALA-1080; ALA-1403; ALA-1508; VAL-1765; VAL-2079 AND
RP   GLU-2373.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PROTEIN SEQUENCE OF 17-27 AND 393-403, AND PROTEOLYTIC PROCESSING BY
RP   AGGRECANASE.
RX   PubMed=7574678; DOI=10.1006/abbi.1995.1431;
RA   Ilic M.Z., Mok M.T., Williamson O.D., Campbell M.A., Hughes C.E.,
RA   Handley C.J.;
RT   "Catabolism of aggrecan by explant cultures of human articular cartilage in
RT   the presence of retinoic acid.";
RL   Arch. Biochem. Biophys. 322:22-30(1995).
RN   [5]
RP   PROTEIN SEQUENCE OF 361-373 AND 393-409, PROTEOLYTIC PROCESSING, AND
RP   GLYCOSYLATION AT THR-371 AND THR-376.
RX   PubMed=1569188; DOI=10.1172/jci115742;
RA   Sandy J.D., Flannery C.R., Neame P.J., Lohmander L.S.;
RT   "The structure of aggrecan fragments in human synovial fluid. Evidence for
RT   the involvement in osteoarthritis of a novel proteinase which cleaves the
RT   Glu 373-Ala 374 bond of the interglobular domain.";
RL   J. Clin. Invest. 89:1512-1516(1992).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 350-497, AND TISSUE SPECIFICITY.
RC   TISSUE=Fetal cartilage;
RX   PubMed=7524681; DOI=10.1016/0167-4781(94)90220-8;
RA   Glumoff V., Savontaus M., Vehanen J., Vuorio E.;
RT   "Analysis of aggrecan and tenascin gene expression in mouse skeletal
RT   tissues by northern and in situ hybridization using species specific cDNA
RT   probes.";
RL   Biochim. Biophys. Acta 1219:613-622(1994).
RN   [7]
RP   PROTEIN SEQUENCE OF 393-409.
RC   TISSUE=Synovial fluid;
RX   PubMed=8216415; DOI=10.1002/art.1780360906;
RA   Lohmander L.S., Neame P.J., Sandy J.D.;
RT   "The structure of aggrecan fragments in human synovial fluid. Evidence that
RT   aggrecanase mediates cartilage degradation in inflammatory joint disease,
RT   joint injury, and osteoarthritis.";
RL   Arthritis Rheum. 36:1214-1222(1993).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 765-866.
RC   TISSUE=Blood;
RX   PubMed=7827755; DOI=10.1016/0945-053x(94)90198-8;
RA   Barry F.P., Neame P.J., Sasse J., Pearson D.;
RT   "Length variation in the keratan sulfate domain of mammalian aggrecan.";
RL   Matrix Biol. 14:323-328(1994).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1893-2530 (ISOFORM 2), AND VARIANTS VAL-2079
RP   AND ARG-2500.
RC   TISSUE=Chondrocyte;
RX   PubMed=8611178; DOI=10.1042/bj3130933;
RA   Dudhia J., Davidson C.M., Wells T.M., Vynios D.H., Hardingham T.E.,
RA   Bayliss M.T.;
RT   "Age-related changes in the content of the C-terminal region of aggrecan in
RT   human articular cartilage.";
RL   Biochem. J. 313:933-940(1996).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2051-2530 (ISOFORM 1), AND VARIANTS VAL-2079
RP   AND ARG-2500.
RX   PubMed=2789216; DOI=10.1016/s0021-9258(18)71537-8;
RA   Baldwin C.T., Reginato A.M., Prockop D.J.;
RT   "A new epidermal growth factor-like domain in the human core protein for
RT   the large cartilage-specific proteoglycan. Evidence for alternative
RT   splicing of the domain.";
RL   J. Biol. Chem. 264:15747-15750(1989).
RN   [11]
RP   INVOLVEMENT IN SEDK.
RX   PubMed=16080123; DOI=10.1086/444401;
RA   Gleghorn L., Ramesar R., Beighton P., Wallis G.;
RT   "A mutation in the variable repeat region of the aggrecan gene (AGC1)
RT   causes a form of spondyloepiphyseal dysplasia associated with severe,
RT   premature osteoarthritis.";
RL   Am. J. Hum. Genet. 77:484-490(2005).
RN   [12]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-658.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J.,
RA   Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [13]
RP   INTERACTION WITH COMP.
RX   PubMed=17588949; DOI=10.1074/jbc.m611390200;
RA   Chen F.-H., Herndon M.E., Patel N., Hecht J.T., Tuan R.S., Lawler J.;
RT   "Interaction of cartilage oligomeric matrix protein/thrombospondin 5 with
RT   aggrecan.";
RL   J. Biol. Chem. 282:24591-24598(2007).
RN   [14]
RP   VARIANT SEMDAG ASN-2381, AND CHARACTERIZATION OF VARIANT SEMDAG ASN-2381.
RX   PubMed=19110214; DOI=10.1016/j.ajhg.2008.12.001;
RA   Tompson S.W., Merriman B., Funari V.A., Fresquet M., Lachman R.S.,
RA   Rimoin D.L., Nelson S.F., Briggs M.D., Cohn D.H., Krakow D.;
RT   "A recessive skeletal dysplasia, SEMD aggrecan type, results from a
RT   missense mutation affecting the C-type lectin domain of aggrecan.";
RL   Am. J. Hum. Genet. 84:72-79(2009).
RN   [15]
RP   VARIANT SSOAOD MET-2418, AND DETECTION OF VARIANT SSOAOD MET-2418 BY MASS
RP   SPECTROMETRY.
RX   PubMed=20137779; DOI=10.1016/j.ajhg.2009.12.018;
RA   Stattin E.L., Wiklund F., Lindblom K., Onnerfjord P., Jonsson B.A.,
RA   Tegner Y., Sasaki T., Struglics A., Lohmander S., Dahl N., Heinegard D.,
RA   Aspberg A.;
RT   "A missense mutation in the aggrecan C-type lectin domain disrupts
RT   extracellular matrix interactions and causes dominant familial
RT   osteochondritis dissecans.";
RL   Am. J. Hum. Genet. 86:126-137(2010).
CC   -!- FUNCTION: This proteoglycan is a major component of extracellular
CC       matrix of cartilagenous tissues. A major function of this protein is to
CC       resist compression in cartilage. It binds avidly to hyaluronic acid via
CC       an N-terminal globular region.
CC   -!- SUBUNIT: Interacts with FBLN1 (By similarity). Interacts with COMP.
CC       {ECO:0000250, ECO:0000269|PubMed:17588949}.
CC   -!- INTERACTION:
CC       P16112; P05067: APP; NbExp=3; IntAct=EBI-9076211, EBI-77613;
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P16112-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P16112-2; Sequence=VSP_003074;
CC       Name=3;
CC         IsoId=P16112-3; Sequence=VSP_003074, VSP_003075;
CC   -!- TISSUE SPECIFICITY: Restricted to cartilages.
CC       {ECO:0000269|PubMed:7524681}.
CC   -!- DEVELOPMENTAL STAGE: Expression was detected in chondrocytes throughout
CC       the developing skeleton.
CC   -!- DOMAIN: Two globular domains, G1 and G2, comprise the N-terminus of the
CC       proteoglycan, while another globular region, G3, makes up the C-
CC       terminus. G1 contains Link domains and thus consists of three
CC       disulfide-bonded loop structures designated as the A, B, B' motifs. G2
CC       is similar to G1. The keratan sulfate (KS) and the chondroitin sulfate
CC       (CS) attachment domains lie between G2 and G3.
CC   -!- PTM: Contains mostly chondroitin sulfate, but also keratan sulfate
CC       chains, N-linked and O-linked oligosaccharides. The release of aggrecan
CC       fragments from articular cartilage into the synovial fluid at all
CC       stages of human osteoarthritis is the result of cleavage by
CC       aggrecanase. {ECO:0000269|PubMed:1569188, ECO:0000269|PubMed:16335952,
CC       ECO:0000269|PubMed:7574678}.
CC   -!- DISEASE: Spondyloepiphyseal dysplasia type Kimberley (SEDK)
CC       [MIM:608361]: Spondyloepiphyseal dysplasias are a heterogeneous group
CC       of congenital chondrodysplasias that specifically affect epiphyses and
CC       vertebrae. The autosomal dominant SEDK is associated with premature
CC       degenerative arthropathy. {ECO:0000269|PubMed:16080123}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Spondyloepimetaphyseal dysplasia, aggrecan type (SEMDAG)
CC       [MIM:612813]: A bone disease characterized by severe short stature,
CC       macrocephaly, severe midface hypoplasia, short neck, barrel chest and
CC       brachydactyly. The radiological findings comprise long bones with
CC       generalized irregular epiphyses with widened metaphyses, especially at
CC       the knees, platyspondyly, and multiple cervical-vertebral clefts.
CC       {ECO:0000269|PubMed:19110214}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Short stature and advanced bone age, with or without early-
CC       onset osteoarthritis and/or osteochondritis dissecans (SSOAOD)
CC       [MIM:165800]: An autosomal dominant disease characterized by short
CC       stature, advanced bone maturation, early-onset osteoarthritis, and mild
CC       dysmorphic features consisting of midface hypoplasia, brachydactyly,
CC       broad great toes, and lumbar lordosis. Other features include
CC       intervertebral disk disease and osteochondritis dissecans.
CC       Osteochondritis dissecans is defined as a separation of cartilage and
CC       subchondral bone from the surrounding tissue.
CC       {ECO:0000269|PubMed:20137779}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the aggrecan/versican proteoglycan family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Functional Glycomics Gateway - Glycan Binding;
CC       Note=Aggrecan;
CC       URL="http://www.functionalglycomics.org/glycomics/GBPServlet?&operationType=view&cbpId=cbp_hum_Ctlect_351";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M55172; AAA62824.1; -; mRNA.
DR   EMBL; AC103982; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC150624; AAI50625.1; -; mRNA.
DR   EMBL; X80278; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; S74659; AAC60643.2; -; Genomic_DNA.
DR   EMBL; X17406; CAA35463.1; -; mRNA.
DR   EMBL; J05062; AAA35726.1; -; mRNA.
DR   CCDS; CCDS53970.1; -. [P16112-1]
DR   CCDS; CCDS53971.1; -. [P16112-3]
DR   PIR; A39086; A39086.
DR   RefSeq; NP_001126.3; NM_001135.3. [P16112-3]
DR   RefSeq; NP_037359.3; NM_013227.3. [P16112-1]
DR   RefSeq; XP_011519616.1; XM_011521314.1. [P16112-2]
DR   PDB; 4MD4; X-ray; 1.95 A; C=89-103.
DR   PDBsum; 4MD4; -.
DR   AlphaFoldDB; P16112; -.
DR   SMR; P16112; -.
DR   IntAct; P16112; 3.
DR   MINT; P16112; -.
DR   STRING; 9606.ENSP00000387356; -.
DR   DrugBank; DB02255; Ilomastat.
DR   GlyConnect; 2002; 3 N-Linked glycans (1 site).
DR   GlyGen; P16112; 82 sites, 5 N-linked glycans (1 site), 8 O-linked glycans (73 sites).
DR   iPTMnet; P16112; -.
DR   PhosphoSitePlus; P16112; -.
DR   BioMuta; ACAN; -.
DR   DMDM; 129886; -.
DR   jPOST; P16112; -.
DR   MassIVE; P16112; -.
DR   PeptideAtlas; P16112; -.
DR   PRIDE; P16112; -.
DR   ProteomicsDB; 17235; -.
DR   ProteomicsDB; 19009; -.
DR   ProteomicsDB; 40179; -.
DR   ProteomicsDB; 53288; -. [P16112-1]
DR   ProteomicsDB; 53289; -. [P16112-2]
DR   ProteomicsDB; 53290; -. [P16112-3]
DR   Antibodypedia; 4288; 547 antibodies from 32 providers.
DR   DNASU; 176; -.
DR   Ensembl; ENST00000352105.11; ENSP00000341615.7; ENSG00000157766.19. [P16112-3]
DR   Ensembl; ENST00000439576.7; ENSP00000387356.2; ENSG00000157766.19. [P16112-1]
DR   Ensembl; ENST00000559004.5; ENSP00000453499.1; ENSG00000157766.19. [P16112-2]
DR   GeneID; 176; -.
DR   KEGG; hsa:176; -.
DR   UCSC; uc010upo.1; human.
DR   CTD; 176; -.
DR   DisGeNET; 176; -.
DR   GeneCards; ACAN; -.
DR   HGNC; HGNC:319; ACAN.
DR   HPA; ENSG00000157766; Tissue enhanced (brain, seminal vesicle).
DR   MalaCards; ACAN; -.
DR   MIM; 155760; gene.
DR   MIM; 165800; phenotype.
DR   MIM; 608361; phenotype.
DR   MIM; 612813; phenotype.
DR   neXtProt; NX_P16112; -.
DR   OpenTargets; ENSG00000157766; -.
DR   Orphanet; 251262; Familial osteochondritis dissecans.
DR   Orphanet; 435804; Short stature-advanced bone age-early-onset osteoarthritis syndrome.
DR   Orphanet; 171866; Spondyloepimetaphyseal dysplasia, aggrecan type.
DR   Orphanet; 93283; Spondyloepiphyseal dysplasia, Kimberley type.
DR   PharmGKB; PA24616; -.
DR   VEuPathDB; HostDB:ENSG00000157766; -.
DR   eggNOG; ENOG502QUX8; Eukaryota.
DR   GeneTree; ENSGT00940000155971; -.
DR   InParanoid; P16112; -.
DR   PhylomeDB; P16112; -.
DR   TreeFam; TF332134; -.
DR   PathwayCommons; P16112; -.
DR   Reactome; R-HSA-1474228; Degradation of the extracellular matrix.
DR   Reactome; R-HSA-2022854; Keratan sulfate biosynthesis.
DR   Reactome; R-HSA-2022857; Keratan sulfate degradation.
DR   Reactome; R-HSA-3000178; ECM proteoglycans.
DR   Reactome; R-HSA-3656225; Defective CHST6 causes MCDC1.
DR   Reactome; R-HSA-3656243; Defective ST3GAL3 causes MCT12 and EIEE15.
DR   Reactome; R-HSA-3656244; Defective B4GALT1 causes B4GALT1-CDG (CDG-2d).
DR   SignaLink; P16112; -.
DR   SIGNOR; P16112; -.
DR   BioGRID-ORCS; 176; 15 hits in 1074 CRISPR screens.
DR   ChiTaRS; ACAN; human.
DR   GenomeRNAi; 176; -.
DR   Pharos; P16112; Tbio.
DR   PRO; PR:P16112; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; P16112; protein.
DR   Bgee; ENSG00000157766; Expressed in tibia and 149 other tissues.
DR   ExpressionAtlas; P16112; baseline and differential.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; HDA:BHF-UCL.
DR   GO; GO:0031012; C:extracellular matrix; IBA:GO_Central.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005796; C:Golgi lumen; TAS:Reactome.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0030246; F:carbohydrate binding; IEA:UniProtKB-KW.
DR   GO; GO:0005201; F:extracellular matrix structural constituent; TAS:UniProtKB.
DR   GO; GO:0005540; F:hyaluronic acid binding; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0007155; P:cell adhesion; IEA:InterPro.
DR   GO; GO:0007417; P:central nervous system development; IBA:GO_Central.
DR   GO; GO:0006508; P:proteolysis; NAS:UniProtKB.
DR   GO; GO:0001501; P:skeletal system development; IBA:GO_Central.
DR   CDD; cd00033; CCP; 1.
DR   CDD; cd03588; CLECT_CSPGs; 1.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.10.100.10; -; 5.
DR   InterPro; IPR001304; C-type_lectin-like.
DR   InterPro; IPR016186; C-type_lectin-like/link_sf.
DR   InterPro; IPR018378; C-type_lectin_CS.
DR   InterPro; IPR033987; CSPG_CTLD.
DR   InterPro; IPR016187; CTDL_fold.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003006; Ig/MHC_CS.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR013106; Ig_V-set.
DR   InterPro; IPR000538; Link_dom.
DR   InterPro; IPR035976; Sushi/SCR/CCP_sf.
DR   InterPro; IPR000436; Sushi_SCR_CCP_dom.
DR   Pfam; PF00059; Lectin_C; 1.
DR   Pfam; PF00084; Sushi; 1.
DR   Pfam; PF07686; V-set; 1.
DR   Pfam; PF00193; Xlink; 4.
DR   PRINTS; PR01265; LINKMODULE.
DR   SMART; SM00032; CCP; 1.
DR   SMART; SM00034; CLECT; 1.
DR   SMART; SM00181; EGF; 1.
DR   SMART; SM00409; IG; 1.
DR   SMART; SM00406; IGv; 1.
DR   SMART; SM00445; LINK; 4.
DR   SUPFAM; SSF48726; SSF48726; 1.
DR   SUPFAM; SSF56436; SSF56436; 5.
DR   SUPFAM; SSF57535; SSF57535; 1.
DR   PROSITE; PS00615; C_TYPE_LECTIN_1; 1.
DR   PROSITE; PS50041; C_TYPE_LECTIN_2; 1.
DR   PROSITE; PS00022; EGF_1; 1.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS50026; EGF_3; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00290; IG_MHC; 1.
DR   PROSITE; PS01241; LINK_1; 4.
DR   PROSITE; PS50963; LINK_2; 4.
DR   PROSITE; PS50923; SUSHI; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Direct protein sequencing;
KW   Disease variant; Disulfide bond; Dwarfism; EGF-like domain;
KW   Extracellular matrix; Glycoprotein; Immunoglobulin domain; Lectin;
KW   Metal-binding; Proteoglycan; Reference proteome; Repeat; Secreted; Signal;
KW   Sushi.
FT   SIGNAL          1..16
FT                   /evidence="ECO:0000269|PubMed:7574678"
FT   CHAIN           17..2530
FT                   /note="Aggrecan core protein"
FT                   /id="PRO_0000017505"
FT   CHAIN           393..2530
FT                   /note="Aggrecan core protein 2"
FT                   /id="PRO_0000017506"
FT   DOMAIN          34..147
FT                   /note="Ig-like V-type"
FT   DOMAIN          153..248
FT                   /note="Link 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00323"
FT   DOMAIN          254..350
FT                   /note="Link 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00323"
FT   DOMAIN          478..573
FT                   /note="Link 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00323"
FT   DOMAIN          579..675
FT                   /note="Link 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00323"
FT   REPEAT          773..778
FT                   /note="1-1"
FT   REPEAT          779..784
FT                   /note="1-2"
FT   REPEAT          785..790
FT                   /note="1-3"
FT   REPEAT          791..796
FT                   /note="1-4"
FT   REPEAT          797..802
FT                   /note="1-5"
FT   REPEAT          803..808
FT                   /note="1-6"
FT   REPEAT          809..814
FT                   /note="1-7; approximate"
FT   REPEAT          815..820
FT                   /note="1-8; approximate"
FT   REPEAT          821..826
FT                   /note="1-9"
FT   REPEAT          827..832
FT                   /note="1-10; approximate"
FT   REPEAT          833..838
FT                   /note="1-11"
FT   REPEAT          839..844
FT                   /note="1-12"
FT   REPEAT          942..960
FT                   /note="2-1"
FT   REPEAT          961..979
FT                   /note="2-2"
FT   REPEAT          980..998
FT                   /note="2-3"
FT   REPEAT          999..1017
FT                   /note="2-4"
FT   REPEAT          1018..1036
FT                   /note="2-5"
FT   REPEAT          1037..1055
FT                   /note="2-6"
FT   REPEAT          1056..1074
FT                   /note="2-7"
FT   REPEAT          1075..1093
FT                   /note="2-8"
FT   REPEAT          1094..1112
FT                   /note="2-9"
FT   REPEAT          1113..1131
FT                   /note="2-10"
FT   REPEAT          1132..1150
FT                   /note="2-11"
FT   REPEAT          1151..1169
FT                   /note="2-12"
FT   REPEAT          1170..1188
FT                   /note="2-13"
FT   REPEAT          1189..1207
FT                   /note="2-14"
FT   REPEAT          1208..1226
FT                   /note="2-15"
FT   REPEAT          1227..1245
FT                   /note="2-16"
FT   REPEAT          1246..1264
FT                   /note="2-17"
FT   REPEAT          1265..1283
FT                   /note="2-18"
FT   REPEAT          1284..1302
FT                   /note="2-19"
FT   REPEAT          1303..1321
FT                   /note="2-20"
FT   REPEAT          1322..1340
FT                   /note="2-21"
FT   REPEAT          1341..1359
FT                   /note="2-22"
FT   REPEAT          1360..1378
FT                   /note="2-23"
FT   REPEAT          1379..1397
FT                   /note="2-24"
FT   REPEAT          1398..1416
FT                   /note="2-25"
FT   REPEAT          1417..1435
FT                   /note="2-26"
FT   REPEAT          1436..1454
FT                   /note="2-27"
FT   REPEAT          1455..1473
FT                   /note="2-28"
FT   REPEAT          1475..1493
FT                   /note="2-29"
FT   REPEAT          1494..1512
FT                   /note="2-30"
FT   REPEAT          1513..1531
FT                   /note="2-31"
FT   REPEAT          1533..1551
FT                   /note="2-32"
FT   REPEAT          1553..1572
FT                   /note="2-33; approximate"
FT   REPEAT          1574..1592
FT                   /note="2-34"
FT   REPEAT          1594..1612
FT                   /note="2-35"
FT   DOMAIN          2279..2314
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          2327..2441
FT                   /note="C-type lectin"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00040"
FT   DOMAIN          2445..2505
FT                   /note="Sushi"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00302"
FT   REGION          48..141
FT                   /note="G1-A"
FT   REGION          152..247
FT                   /note="G1-B"
FT   REGION          253..349
FT                   /note="G1-B'"
FT   REGION          477..571
FT                   /note="G2-B"
FT   REGION          578..673
FT                   /note="G2-B'"
FT   REGION          677..849
FT                   /note="KS"
FT   REGION          734..979
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          773..844
FT                   /note="12 X 6 AA approximate tandem repeats of E-[GVE]-P-
FT                   [SFY]-[APT]-[TSP]"
FT   REGION          852..1612
FT                   /note="CS-1"
FT   REGION          942..1612
FT                   /note="35 X 19 AA approximate tandem repeats of E-[IVDG]-
FT                   [LV]-[EV]-[GTI]-[STA]-[ATV]-[SP]-[GA]-[VIFAD]-[GEDL]-[DE]-
FT                   [LVI]-[SG]-[GERK]-[LV]-P-S-G"
FT   REGION          1499..1526
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1543..1649
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1613..2277
FT                   /note="CS-2"
FT   REGION          1687..1772
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1784..1827
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1883..1902
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1948..1977
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2048..2204
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2249..2281
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2278..2530
FT                   /note="G3"
FT   REGION          2510..2530
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        765..785
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        792..808
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        898..913
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1615..1629
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1709..1723
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1739..1772
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1812..1827
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2048..2077
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2093..2107
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2126..2159
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2166..2204
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2513..2530
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         2381
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250"
FT   BINDING         2385
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250"
FT   BINDING         2385
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000250"
FT   BINDING         2405
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250"
FT   BINDING         2407
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250"
FT   BINDING         2408
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250"
FT   BINDING         2414
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250"
FT   BINDING         2414
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250"
FT   BINDING         2415
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250"
FT   BINDING         2415
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000250"
FT   BINDING         2428
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250"
FT   BINDING         2429
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250"
FT   SITE            392..393
FT                   /note="Cleavage; by aggrecanase"
FT   CARBOHYD        126
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        239
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        333
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        371
FT                   /note="O-linked (Xyl...) (keratan sulfate) threonine"
FT                   /evidence="ECO:0000305|PubMed:1569188"
FT   CARBOHYD        376
FT                   /note="O-linked (Xyl...) (keratan sulfate) threonine"
FT                   /evidence="ECO:0000305|PubMed:1569188"
FT   CARBOHYD        387
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        434
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        602
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        658
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16335952"
FT   CARBOHYD        738
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        2013
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        51..133
FT                   /evidence="ECO:0000250"
FT   DISULFID        175..246
FT                   /evidence="ECO:0000250"
FT   DISULFID        199..220
FT                   /evidence="ECO:0000250"
FT   DISULFID        273..348
FT                   /evidence="ECO:0000250"
FT   DISULFID        297..318
FT                   /evidence="ECO:0000250"
FT   DISULFID        500..571
FT                   /evidence="ECO:0000250"
FT   DISULFID        524..545
FT                   /evidence="ECO:0000250"
FT   DISULFID        598..673
FT                   /evidence="ECO:0000250"
FT   DISULFID        622..643
FT                   /evidence="ECO:0000250"
FT   DISULFID        2283..2293
FT                   /evidence="ECO:0000250"
FT   DISULFID        2288..2302
FT                   /evidence="ECO:0000250"
FT   DISULFID        2304..2313
FT                   /evidence="ECO:0000250"
FT   DISULFID        2320..2331
FT                   /evidence="ECO:0000250"
FT   DISULFID        2348..2440
FT                   /evidence="ECO:0000250"
FT   DISULFID        2416..2432
FT                   /evidence="ECO:0000250"
FT   DISULFID        2447..2490
FT                   /evidence="ECO:0000250"
FT   DISULFID        2476..2503
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         2278..2315
FT                   /note="Missing (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:1985970,
FT                   ECO:0000303|PubMed:8611178"
FT                   /id="VSP_003074"
FT   VAR_SEQ         2445..2506
FT                   /note="VACGEPPVVEHARTFGQKKDRYEINSLVRYQCTEGFVQRHMPTIRCQPSGHW
FT                   EEPQITCTDP -> A (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:1985970"
FT                   /id="VSP_003075"
FT   VARIANT         102
FT                   /note="D -> E (in dbSNP:rs16942318)"
FT                   /id="VAR_056152"
FT   VARIANT         275
FT                   /note="R -> Q (in dbSNP:rs34949187)"
FT                   /id="VAR_056153"
FT   VARIANT         864
FT                   /note="P -> L (in dbSNP:rs3743398)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_080159"
FT   VARIANT         913
FT                   /note="P -> T (in dbSNP:rs35430524)"
FT                   /evidence="ECO:0000269|PubMed:1985970"
FT                   /id="VAR_080160"
FT   VARIANT         930
FT                   /note="S -> I (in dbSNP:rs938608)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_080161"
FT   VARIANT         939
FT                   /note="S -> T (in dbSNP:rs938609)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_080162"
FT   VARIANT         1080
FT                   /note="T -> A (in dbSNP:rs373544100)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_080163"
FT   VARIANT         1403
FT                   /note="T -> A (in dbSNP:rs12899191)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_080164"
FT   VARIANT         1508
FT                   /note="E -> A (in dbSNP:rs2882676)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_080165"
FT   VARIANT         1765
FT                   /note="I -> V (in dbSNP:rs4932439)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:1985970"
FT                   /id="VAR_080166"
FT   VARIANT         2058
FT                   /note="P -> L (in dbSNP:rs35061438)"
FT                   /id="VAR_056154"
FT   VARIANT         2079
FT                   /note="I -> V (in dbSNP:rs1042630)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:2789216, ECO:0000269|PubMed:8611178"
FT                   /id="VAR_080167"
FT   VARIANT         2120
FT                   /note="S -> R (in dbSNP:rs34153007)"
FT                   /id="VAR_056155"
FT   VARIANT         2373
FT                   /note="D -> E (in dbSNP:rs3817428)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_080168"
FT   VARIANT         2381
FT                   /note="D -> N (in SEMDAG; creates a functional
FT                   N-glycosylation site; does not adversely affect protein
FT                   trafficking and secretion; dbSNP:rs121913568)"
FT                   /evidence="ECO:0000269|PubMed:19110214"
FT                   /id="VAR_063053"
FT   VARIANT         2418
FT                   /note="V -> M (in SSOAOD; dbSNP:rs779794758)"
FT                   /evidence="ECO:0000269|PubMed:20137779"
FT                   /id="VAR_063765"
FT   VARIANT         2500
FT                   /note="Q -> R (in dbSNP:rs1126823)"
FT                   /evidence="ECO:0000269|PubMed:2789216,
FT                   ECO:0000269|PubMed:8611178"
FT                   /id="VAR_080169"
FT   CONFLICT        285..286
FT                   /note="QL -> HV (in Ref. 1; AAA62824)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        501..502
FT                   /note="LR -> PG (in Ref. 1; AAA62824)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        605
FT                   /note="Missing (in Ref. 1; AAA62824)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        767
FT                   /note="A -> E (in Ref. 1; AAA62824)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        848
FT                   /note="V -> E (in Ref. 1; AAA62824)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        999..1017
FT                   /note="Missing (in Ref. 3; AAI50625)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1075..1188
FT                   /note="Missing (in Ref. 1; AAA62824)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1548
FT                   /note="L -> V (in Ref. 1; AAA62824)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2043
FT                   /note="E -> A (in Ref. 9; CAA35463)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2185
FT                   /note="P -> A (in Ref. 10; AAA35726)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   2530 AA;  261329 MW;  3C809F6DE829956B CRC64;
     MTTLLWVFVT LRVITAAVTV ETSDHDNSLS VSIPQPSPLR VLLGTSLTIP CYFIDPMHPV
     TTAPSTAPLA PRIKWSRVSK EKEVVLLVAT EGRVRVNSAY QDKVSLPNYP AIPSDATLEV
     QSLRSNDSGV YRCEVMHGIE DSEATLEVVV KGIVFHYRAI STRYTLDFDR AQRACLQNSA
     IIATPEQLQA AYEDGFHQCD AGWLADQTVR YPIHTPREGC YGDKDEFPGV RTYGIRDTNE
     TYDVYCFAEE MEGEVFYATS PEKFTFQEAA NECRRLGARL ATTGQLYLAW QAGMDMCSAG
     WLADRSVRYP ISKARPNCGG NLLGVRTVYV HANQTGYPDP SSRYDAICYT GEDFVDIPEN
     FFGVGGEEDI TVQTVTWPDM ELPLPRNITE GEARGSVILT VKPIFEVSPS PLEPEEPFTF
     APEIGATAFA EVENETGEAT RPWGFPTPGL GPATAFTSED LVVQVTAVPG QPHLPGGVVF
     HYRPGPTRYS LTFEEAQQAC LRTGAVIASP EQLQAAYEAG YEQCDAGWLR DQTVRYPIVS
     PRTPCVGDKD SSPGVRTYGV RPSTETYDVY CFVDRLEGEV FFATRLEQFT FQEALEFCES
     HNATLATTGQ LYAAWSRGLD KCYAGWLADG SLRYPIVTPR PACGGDKPGV RTVYLYPNQT
     GLPDPLSRHH AFCFRGISAV PSPGEEEGGT PTSPSGVEEW IVTQVVPGVA AVPVEEETTA
     VPSGETTAIL EFTTEPENQT EWEPAYTPVG TSPLPGILPT WPPTGAATEE STEGPSATEV
     PSASEEPSPS EVPFPSEEPS PSEEPFPSVR PFPSVELFPS EEPFPSKEPS PSEEPSASEE
     PYTPSPPVPS WTELPSSGEE SGAPDVSGDF TGSGDVSGHL DFSGQLSGDR ASGLPSGDLD
     SSGLTSTVGS GLPVESGLPS GDEERIEWPS TPTVGELPSG AEILEGSASG VGDLSGLPSG
     EVLETSASGV GDLSGLPSGE VLETTAPGVE DISGLPSGEV LETTAPGVED ISGLPSGEVL
     ETTAPGVEDI SGLPSGEVLE TTAPGVEDIS GLPSGEVLET TAPGVEDISG LPSGEVLETT
     APGVEDISGL PSGEVLETAA PGVEDISGLP SGEVLETAAP GVEDISGLPS GEVLETAAPG
     VEDISGLPSG EVLETAAPGV EDISGLPSGE VLETAAPGVE DISGLPSGEV LETAAPGVED
     ISGLPSGEVL ETAAPGVEDI SGLPSGEVLE TAAPGVEDIS GLPSGEVLET AAPGVEDISG
     LPSGEVLETA APGVEDISGL PSGEVLETAA PGVEDISGLP SGEVLETAAP GVEDISGLPS
     GEVLETAAPG VEDISGLPSG EVLETAAPGV EDISGLPSGE VLETAAPGVE DISGLPSGEV
     LETAAPGVED ISGLPSGEVL ETTAPGVEEI SGLPSGEVLE TTAPGVDEIS GLPSGEVLET
     TAPGVEEISG LPSGEVLETS TSAVGDLSGL PSGGEVLEIS VSGVEDISGL PSGEVVETSA
     SGIEDVSELP SGEGLETSAS GVEDLSRLPS GEEVLEISAS GFGDLSGLPS GGEGLETSAS
     EVGTDLSGLP SGREGLETSA SGAEDLSGLP SGKEDLVGSA SGDLDLGKLP SGTLGSGQAP
     ETSGLPSGFS GEYSGVDLGS GPPSGLPDFS GLPSGFPTVS LVDSTLVEVV TASTASELEG
     RGTIGISGAG EISGLPSSEL DISGRASGLP SGTELSGQAS GSPDVSGEIP GLFGVSGQPS
     GFPDTSGETS GVTELSGLSS GQPGISGEAS GVLYGTSQPF GITDLSGETS GVPDLSGQPS
     GLPGFSGATS GVPDLVSGTT SGSGESSGIT FVDTSLVEVA PTTFKEEEGL GSVELSGLPS
     GEADLSGKSG MVDVSGQFSG TVDSSGFTSQ TPEFSGLPSG IAEVSGESSR AEIGSSLPSG
     AYYGSGTPSS FPTVSLVDRT LVESVTQAPT AQEAGEGPSG ILELSGAHSG APDMSGEHSG
     FLDLSGLQSG LIEPSGEPPG TPYFSGDFAS TTNVSGESSV AMGTSGEASG LPEVTLITSE
     FVEGVTEPTI SQELGQRPPV THTPQLFESS GKVSTAGDIS GATPVLPGSG VEVSSVPESS
     SETSAYPEAG FGASAAPEAS REDSGSPDLS ETTSAFHEAN LERSSGLGVS GSTLTFQEGE
     ASAAPEVSGE STTTSDVGTE APGLPSATPT ASGDRTEISG DLSGHTSQLG VVISTSIPES
     EWTQQTQRPA ETHLEIESSS LLYSGEETHT VETATSPTDA SIPASPEWKR ESESTAAAPA
     RSCAEEPCGA GTCKETEGHV ICLCPPGYTG EHCNIDQEVC EEGWNKYQGH CYRHFPDRET
     WVDAERRCRE QQSHLSSIVT PEEQEFVNNN AQDYQWIGLN DRTIEGDFRW SDGHPMQFEN
     WRPNQPDNFF AAGEDCVVMI WHEKGEWNDV PCNYHLPFTC KKGTVACGEP PVVEHARTFG
     QKKDRYEINS LVRYQCTEGF VQRHMPTIRC QPSGHWEEPQ ITCTDPTTYK RRLQKRSSRH
     PRRSRPSTAH
//
